Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
yep the action like that is usually a tell ;)
agreed..and as per last 10q sure sounds like soon imo..not to mention the action outta nowhere recently too could be the sign!
as soon as nice PR hits... she should go ;)
ALPS faking the funk imo lol they be outtie soon imo!)
nice nice!)lets do this bro!)
only filled me 10k there
good idea.. i just sent an order to .031.. let's see how many alps has there ;) level2 ask pretty clear after alps
got a few more jus now..think im goin to start dabbling down here again in the nearterm here and there jus in case this gets the big news we been waiting on!FDA clearance for their nitrous oxide system would be the ticket!
from last 10q..
Nitric Oxide Gas for Inhalation
We are a medical research and development company specializing in pharmaceutical, bio-technical and medical gas generating systems. The primary gas our systems will generate is medical grade nitric oxide, along with other various combinations of beneficial medical gases suitable for the treatment of human conditions and diseases. The gases also have other potential uses, such as the treatment of animals by veterinarians and the sterilization of equipment and devices.
Non-medical grade nitric oxide gas is produced and sold commercially by major gas companies as a specialty gas mixture and calibration gas. Nitrogen dioxide is present in all nitric oxide gas currently produced. Its presence limits the size of the dose of nitric oxide gas that can be administered for prospective uses in both humans and animals.
We have developed a proprietary compound formulation that will be utilized to produce medical grade nitric oxide gas in our desktop and portable generators. Management believes that with the further refinement of our proprietary formulation, we can make or filter medical grade nitric oxide gas with minimal amounts of nitrogen dioxide, and that this process can produce medical grade nitric oxide gas in ample quantities for any current or prospective use and at a price substantially less than that of all currently available technologies.
Our current generator models are capable of delivering sufficient quantities of nitric oxide gas for individual laboratory desktop use. We are continuing to further develop our generators and our proprietary compound formulation for high production quantities and consistency. The product must have a known shelf life and be available in various configurations to produce known concentrations and volumes of gas. Packaging is another critical developmental process that we are addressing. Management plans to rely on outside contractors to achieve these objectives.
We estimate that non-clinical laboratory sales could take place earlier than United States Food and Drug Administration (“FDA”) approval. Management anticipates that selling our desktop generator earlier into the market as laboratory equipment will pave the way for sales of our medical generators and proprietary tablets and compounds, but expected financial contributions from non-medical generator and tablet sales will not be sufficient to fund the substantial costs of the FDA approval process for human medical uses. We expect that contributions from laboratory sales will be able to cover all or part of our manufacturing and set-up costs and contribute to our overall profitability in due time, but believe that we will also require additional funding, which we are currently working to secure.
All human medical uses of nitric oxide gas require FDA approval prior to initiating sales in the United States, and the approval of similar international agencies in their respective countries. Approval can be a long and expensive process, with no assurance that any such approval can or will ever be obtained. Management hopes to reduce the time for regulatory approval by certain strategic approaches that are proprietary.
Our objectives are to establish GeNOsys (generated nitric oxide systems) as the premier nitric oxide generating pharmaceutical company and to:
-manufacture and sell medical grade nitric oxide generators and tablets and compounds for use in the relief of human diseases;
-offer value added services such as custom generators adapted for the treatment of various diseases
-hire staff both currently identified and unidentified to implement our business model; and
-obtain FDA approval of our generating systems.
Nitric Oxide Producing Topical Products
We have developed a group of nitric oxide producing products for topical use. Patent applications have been filed for these products, which will be available as a cream, gel or wash, depending on the desired application and use.
There are significant markets for topical nitric oxide producing products, including use on non-healing wounds (diabetic ulcers, etc.) and skin care (acne, rashes, abrasions, etc.). For use on non-healing wounds, nitric oxide producing topical products will, with their vasodilator properties, support blood flow to the wound area and support collagen growth, with their anti-inflammatory properties they will reduce inflammation in the wound area, and with their antibacterial properties, support the body in clearing the wound area of infection. We are currently working with a wound care clinic to finalize the procedures for use on non-healing wounds. It is anticipated that revenues will begin to be generated from these topical nitric oxide producing products during the fourth quarter of 2011.
welcome aboard!
nice bids poppin up now!
hopin so!would only be fitting!
would probably explode with heavy volume
somethings up ? ;)
forgot how thin this puppy is!come on news and pressure!!
waking brotha!039 taken out 06s up!
we know how quick that can change with a FDA PR er big filing!)))
off most people's radars.. for now
yep this could fly with the right pr
nice to see!somethin!!heres to major wakeage here soon OUTTA NOWHERE!!!bring it!)
would love to get some good news here soon to kick off the year here!!holdin my tickets!
nice nice..
ima lurk fer biddies myself
yep! i recently added ;)
still waiting/holdin patiently for their fda approval to sell/market their device!!bring it!)we know what haps if they announce it outta nowhere with this OS!))DF
maybe some impatient holders come along... doubt it though
dang
id love some 02s prolly wont hap ugh lol big spread
wow very nice news imo!
and pps cheap too!
GeNOsys Completes License Agreements
Press Release Source: GeNOsys, Inc. On Thursday October 6, 2011, 8:00 am EDT
PROVO, Utah--(BUSINESS WIRE)-- GeNOsys, Inc. (OTCBB:GNYS.ob - News) today announced it has, through its wholly owned subsidiary Health Innovations Inc., entered into two license agreement with Equity Labs, Inc. The agreements enable Equity Labs to manufacture and distribute some of the nitric oxide topical products developed by GeNOsys. An exclusive license has been entered into for an acne product, and a non-exclusive license covers a line of products for topical skin care.
“These license agreements are a significant milestone for GeNOsys, representing our first commercialized products. Equity Labs has a proven record of successful product introductions, and has demonstrated the ability to penetrate and gain market share in new markets,” stated Dale Fillmore, President of GeNOsys. “Equity Labs has distribution channels in place which will facilitate rapid entry into their target markets.”
“We are very excited about the opportunity to introduce these innovative and unique products into the marketplace,” said Steve Chadwick, President of Equity Labs. “We view this as a great opportunity for our Company, and look forward to a long and mutually profitable relationship with GeNOsys.”
“We are pleased with the relationship developed with Equity Labs for marketing our topical products. Development continues to progress well on our nitric oxide gas generator and the related product portfolio,” stated John W.R. Miller, Chairman of GeNOsys, Inc. “We anticipate providing some very positive updates on those projects in the near future.”
About GeNOsys:
GeNOsys, Inc. (generated nitric oxide systems) is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems. Nitric oxide gas will be one of the medical gases that will be generated along with various combinations of beneficial medical gases suitable for the control of human disease. Distribution will be accelerated through the use of already existing distribution networks that currently sell related respiratory products. For further information, see the Company’s Website at: www.genosysusa.com.
About Equity Labs:
Equity Labs, Inc. was incorporated in 2000. Over the past 11 years, Equity Labs has been successful in developing and marketing numerous new and innovative products in the dietary supplements and topical personal care product areas, with emphasis on proprietary products backed by science. Equity Labs products are sold to customers throughout the Americas, Asia and Europe. Many products that Equity Labs has developed and introduced into the market place are unique, innovative and proprietary, and therefore quickly become top selling products. Products developed by Equity Labs are currently sold via mass market retail, specialty retail, pharmacies, health food stores, direct response and network marketing. Equity Labs holds minority interests in several facilities which manufacture and package capsules, tablets and personal care products.
This press release may contain forward-looking statements, including the Company’s beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company’s filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change, and therefore those forecasts speak only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them, and if it should do so, it will disseminate the updates to the investing public.
Contact:
GeNOsys, Inc.Keith Merrell, 801-623-4751kmerrell@genosysusa.com
nice nice imo!))
ima try n do the same asap
i added .035s.. too quiet for too long imo
thoughts about where this one is going...? i thought we had some decent news with a new president appointed, Dale Fillmore.. since then, prices have been down but then again the whole market is crappy..
heard that... i may load up a little more...
ditto but i need more shares before it does so..
hopin fer biddiesssssss while we wait!))
getting a little antsy, hope this moves soon but if not, i have problem waiting for it too.
GM bro!)yup cant wait til the masses take notice all i know!)id say float near nada imo
slow quiet mover liking it ;)
right on well hopefully this 1 makes us all happy..and soon!))
check PR from May about new directors added and their HUGE background..with a multi billion dollar company..i havent seen a pennystock otc with big names like this on board in some time..if ever..will see what haps
awesome.. im still a rookie when it comes to this but feel we have a good one.. time will tell..
good luck to ya!
GM!)i think its bout that time fer this to wake too..
few things happen here and its game on imo..the pieces of the puzzle are being put together imo!)
public reply:
was doing a little research and looks like GNYS is the start of a decent run...
any insight? opinions?
i agree i have no prob waiting til fruition whether it haps days er months from now!)
maybe not today but i think this one will make us in this early very happy
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
205
|
Created
|
10/19/08
|
Type
|
Free
|
Moderators |
GeNOsys, Inc. Reports Recent Developments and Third Quarter 2008 Financial Results
PROVO, UT, Oct 16, 2008 (MARKET WIRE via COMTEX) -- GeNOsys, Inc. (OTCBB: GNYS), a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems, today announced recent key achievements and financial results for the third quarter and first nine months ended August 31, 2008.
Recent Business Development Milestones
-- Completed the research and development, engineering and construction
of the GeNOx-B and portable GeNOx-P Nitric Oxide Gas Generators. The
Company has been issued a patent on the GeNOx-B and has applied for a
patent on the GeNOx-P.
-- Completed preliminary research and development on the proprietary
tablet medium GeNOx-Tablet. Additionally, a formula for the bulk
manufacture of the tablet medium has been formulated. This formula will be
essential to carry out the business model of the Company as a commercially
viable reoccurring revenue producer of Nitric Oxide Gas Generators.
"The third quarter of fiscal 2008 was another active and productive period for GeNOsys, highlighted by the completion of the GeNOx-B and portable GeNOx-P Nitric Oxide Gas Generators," said Mr. Clark Mower, Chairman of the Board of Directors of GeNOsys. "Independent research has shown that Nitric Oxide gas, an FDA approved drug for use in the treatment of pulmonary hypertension in new-borns, may be an effective agent for the treatment of tuberculosis. Through our technology we are able to generate high purity Nitric Oxide for a significantly reduced cost. Now that we have completed this process, our plan includes a multi-track process of FDA and ISO 13485:2003 approvals in order to monetize our products.
Mr. Mower continued, "GeNOsys has a very large opportunity through the commercialization of our generators. Despite infecting nearly two billion people with the bacteria, which is one-third of the world's population, tuberculosis is "The Forgotten Plague," according to a recent article in Time magazine. The World Health Organization states that no new class of drug has been developed for its treatment in over thirty years. By 2010, the market for anti-tuberculosis drugs is projected to be between $612 and $670 million. The potential market for a new anti-tuberculosis drug is estimated to be between $316 and $345 million according to The Global Alliance for Tuberculosis Drug Development. Additionally, our research has shown that there are several other markets in which our generators have the potential to be used."
Financial results for the three months ended August 31, 2008
During the three-month period ended August 31, 2008, GeNOsys had a net loss of $332,349. This compares to a net loss of $239,738 for the comparable period ended August 31, 2007. Net loss per common share for each of the three month periods was $(.01).
Research and development ("R&D") expenses were $185,129 and $120,163, respectively, for the three-month periods ended August 31, 2008, and 2007, an increase of $64,966. The increase results from non-cash stock-based compensation charges, which were $15,488 higher in the 2008 period, from consulting and advisory board fees, and for additional work on both the nitric oxide generator and the tablet formulation to bring them to finalization. As the work on document preparation and regulatory work for FDA approval intensifies, R&D expenses are expected to increase.
General and administrative expenses were $147,152 and $122,907, respectively, for the three-month periods ended August 31, 2008 and 2007, an increase of $24,245. The increase results from the non-cash stock-based compensation charge, which was $22,287 higher in 2008 than in the comparable 2007 period. Excluding that charge, general and administrative expenses would have remained flat in 2008 as compared to 2007. General and administrative expenses are expected to continue to increase in the remaining periods of this fiscal year as expenses were incurred in raising the additional capital needed to fund our operations and bring our products to market.
Financial results for the nine months ended August 31, 2008
During the nine-month period ended August 31, 2008, GeNOsys had a net loss of $970,224. This compares to a net loss of $657,293 for the comparable period ended August 31, 2007. Net loss per common share for these periods was $(.02) and $(.01), respectively.
Research and development ("R&D") expenses were $515,832 and $319,086, respectively, for the nine-month periods ended August 31, 2008 and 2007. A significant portion of the $196,746 increase in research and development expenditures resulted from higher non-cash stock-based compensation charges in 2008, which exceeded the 2007 charge by $92,326. Increases were also seen in consulting fees and advisory board fees for additional work on both the nitric oxide generator and the tablet formulation. As the documentation preparation and regulatory work for FDA approval intensifies, R&D expenses are expected to increase.
General and administrative expenses were $456,656 and $355,396, respectively, for the nine-month periods ended August 31, 2008 and 2007. The increase results from non-cash stock-based compensation charges, which were $132,859 higher in 2008 than 2007. Excluding that charge, general and administrative expenses would have decreased by $31,599 in 2008 as compared to 2007. General and administrative expenses are expected to continue to increase in the remaining periods of this fiscal year as expenses are incurred in raising the additional capital needed to fund operations and bring the products to market.
About GeNOsys, Inc.
GeNOsys, Inc. (generated nitric oxide systems) is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems. Nitric oxide gas is one of the medical gases that will be generated along with various combinations of beneficial medical gases suitable for the control of human disease. Distribution will be accelerated through the use of already existing distribution networks that currently sell related respiratory products. For further information, see the Company's Website at: www.genosysusa.com.
This press release may contain forward-looking statements including the Company's beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company's filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change and therefore those forecasts speak only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public.
GENOSYS, INC. AND SUBSIDIARIES
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
From
Beginning
of
Development
Stage
(June 30,
2005)
For the Three Months For the Nine Months To August
Ended August 31, Ended August 31, 31,
2008 2007 2008 2007 2008
----------- ----------- ----------- ----------- -----------
Revenues $ - $ - $ - $ - $ -
Cost of sales - - - - -
----------- ----------- ----------- ----------- -----------
Gross margin - - - - -
Operating
expenses:
Research and
development 185,129 120,163 515,832 319,086 1,735,288
General and
administra-
tive 147,152 122,907 456,656 355,396 1,733,279
----------- ----------- ----------- ----------- -----------
Total
operating
expenses 332,281 243,070 972,488 674,482 3,468,567
----------- ----------- ----------- ----------- -----------
Net income
(loss) from
operations (332,281) (243,070) (972,488) (674,482) (3,468,567)
----------- ----------- ----------- ----------- -----------
Other income
(expense):
Interest
income 47 3,332 2,379 17,503 82,198
Gain (loss)
on disposal
of asset - - - (414) (414)
Other income
(expense) - - - 100 100
----------- ----------- ----------- ----------- -----------
Total other
income
(expense),
net 47 3,332 2,379 17,189 81,884
----------- ----------- ----------- ----------- -----------
Net income
(loss) before
income Taxes (332,234) (239,738) (970,109) (657,293) (3,386,683)
----------- ----------- ----------- ----------- -----------
Provision
(benefit) for
income Tax 115 - 115 - 415
----------- ----------- ----------- ----------- -----------
Income (loss)
from continuing
operations (332,349) (239,738) (970,224) (657,293) (3,387,098)
Discontinued
operations:
Loss from
discontinued
operations,
net of tax - - - - (2,131)
Gain on
disposal of
discontinued
operations,
net of tax - - - - 71,253
----------- ----------- ----------- ----------- -----------
Net income
(loss) $ (332,349)$ (239,738) $ (970,224)$ (657,293)$(3,317,976)
=========== =========== =========== =========== ===========
Basic and
diluted loss
per share from
continuing
operations $ (.01)$ (.01)$ (.02)$ (.01)$ (.07)
=========== =========== =========== =========== ===========
Basic and
diluted loss
per share from
discontinued
operations $ - $ - $ - $ - $ -
=========== =========== =========== =========== ===========
Basic and
diluted loss
per share $ (.01)$ (.01)$ (.02)$ (.01)$ (.07)
=========== =========== =========== =========== ===========
Basic and
diluted
weighted
average
number of
common shares
outstanding 46,148,787 45,668,031 46,002,850 45,668,031 45,252,720
=========== =========== =========== =========== ===========
GENOSYS, INC. AND SUBSIDIARIES
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
From
Beginning
of
Development
For the Nine For the Nine Stage (June
Months Ended Months Ended 30, 2005)
August August to August
31, 2008 31, 2007 31, 2008
------------ ------------ ------------
Cash flows from operating
activities:
Net loss $ (970,224) $ (657,293) $ (3,317,976)
Adjustments to reconcile net
loss to net cash used in
operating activities:
Depreciation and amortization 38,954 34,200 97,135
Gain on the disposal of
discontinued Operations - - (71,253)
Loss on disposal of equipment - 414 414
Stock-based compensation 281,616 56,431 420,355
Decrease in cash from
discontinued operations - - (6,020)
Stock issued for services 8,536 - 278,536
Changes in operating assets
and liabilities:
(Increase) Decrease in
prepaid expenses (37,197) 64,956 (40,943)
Increase (Decrease) in
accounts payable 55,048 14,030 68,197
Increase (Decrease) in
related party liabilities (9,340) - 4,000
Increase (Decrease) in
accrued liabilities 195,522 (38,358) 209,729
Increase (Decrease) in tax
payable - - 200
------------ ------------ ------------
Net cash used in
operating activities (437,085) (525,620) (2,357,626)
------------ ------------ ------------
Cash flows from investing
activities:
Purchase of intangible assets (27,543) (33,634) (69,672)
Purchase of equipment (1,021) (18,200) (207,501)
------------ ------------ ------------
Net cash provided by
(used in) investing
Activities (28,564) (51,834) (277,173)
------------ ------------ ------------
Cash flows from financing
activities:
Issuance of common stock for
cash 153,500 - 2,574,604
Proceeds from related party
loans 36,000 - 36,000
Cash from discontinued
operations - - (19,777)
------------ ------------ ------------
Net cash provided by
financing activities 189,500 - 2,590,827
------------ ------------ ------------
Net increase (decrease) in cash (276,149) (577,454) (43,972)
Cash at beginning of the period 280,105 904,715 47,928
------------ ------------ ------------
Cash at end of the period $ 3,956 $ 327,261 $ 3,956
============ ============ ============
Supplemental Disclosure
Information
Cash paid during the year for:
Interest $ - $ - $ 750
Income/franchise taxes - - 200
Stock issued for services 8,536 - 278,536
============ ============ ============
Contact:
Alliance Advisors, LLC
Alan Sheinwald
President
(914) 669-0222
Email Contact
Mark McPartland
Vice President
(910) 686-0455
Email Contact
GeNOsys, Inc.
Michael Dancy
(801) 746-3570
Email Contact
SOURCE: GeNOsys, Inc.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |